Cipla , India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla, India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Cipla celebrates a significant 30% rise in net profit for Q4 FY25, with revenues growing by 9%. The company emphasizes its ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share ...